Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed solid tumors
• * Advanced metastatic disease
• Measurable or evaluable disease
• Must meet 1 of the following criteria:
• * Failed prior standard therapy
• * Not a candidate for standard therapy
• * Has a disease for which there is no defined standard therapy
• No symptomatic brain metastases
• PATIENT CHARACTERISTICS:
• ECOG functional status 0-2
• Life expectancy ≥ 8 weeks
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Bilirubin normal
• Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 60 mL/min
• AST and ALT ≤ 2.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• No prior anaphylactic reaction or severe allergic reaction to paclitaxel, docetaxel, or gemcitabine hydrochloride
• No active infectious process that will require treatment with antibiotics for \> 4 weeks
• No uncontrolled congestive heart failure
• No symptomatic coronary artery disease or heart block
• No myocardial infarction within the past 3 months
• No peripheral neuropathy ≥ grade 2 from any cause
• PRIOR CONCURRENT THERAPY:
• More than 3 weeks since prior chemotherapy, radiotherapy, or any other treatment
• No prior radiotherapy to \> 25% of bone marrow
• No prior nitrosoureas
• No more than 6 prior courses of alkylating agents
• No more than 2 prior courses of mitomycin C
• No more than 3 prior courses of cytotoxic therapy for metastatic disease
• No concurrent filgrastim (G-CSF), pegfilgrastim, or sargramostim (GM-CSF) during study course 1